FLNA

Filana Therapeutics, Inc.

FLNA

Filana Therapeutics, Inc.

dashboardOverview

paymentsDividend

newspaperNews

Filana Therapeutics, Inc.

FLNA

NASDAQHealthcare

$ 0.7

Stock Score Analysis

20WEAK

HEALTH

Excellent

VALUATION

Not applicable

1 of 5 dimensions have missing or inapplicable inputs and score 0. The total includes these dimensions.

Key Metrics

Market Cap

36.14M

Dividend Yield (Est.)

0.00%

Revenue (TTM)

EPS (TTM)

$-0.87

PER (TTM)

-0.9x

PBR

0.57x

ROE (TTM)

-58.78%

ROA (TTM)

-40.69%

Equity Ratio

62.9%

1W Change

+3.04%

1M Change

-21.15%

6M Change

-42.31%

1Y Change

52W High

$1.83

52W Low

$0.67

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Read full overview

CEORichard Jon Barry

Founded2000

ExchangeNASDAQ

Analyst Ratings

Bullish: 80.0% (36 analysts: Very Bullish 12, Bullish 24)Bullish

80%

Neutral: 17.8% (8 analysts: Neutral 8)Neutral

18%

Bearish: 2.2% (1 analysts: Bearish 1, Very Bearish 0)Bearish

Median Target: $1.00 (45 analysts)Median Target$1.00

45 analysts

EPS Trend

(USD)

2021 Actual: -$0.82

-0.82

212021

2022 Actual: -$1.90

-1.90

222022

2023 Actual: -$2.32

-2.32

232023

2024 Actual: -$0.53

-0.53

242024

2025 Actual: -$1.88 (Est: -$1.93)

-1.93

-1.88

252025

FY2026 Estimate: -$1.02

26 Est.2026 Est.

FY2027 Estimate: $0.09

0.09

27 Est.2027 Est.

Analyst Est.

Actual

5Y Growth-129.3%

Market Sentiment & News

Latest First ▾

Press Release

Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

46 days ago·PRNewsWire

Similar Stocks & Peers

Asset	Price	Div. Yield